- Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasisWu, Yi-Long; Zhou, Qing; Wang, Jie; Yu, Yan; Xing, Ligang; Wang, Ying; Cheng, Ying; Pan, Yueyin; Fan, Yun; Shi, Jianhua; Zhang, Guojun; Cui, Jiuwei; Zhou, Jianying; Song, Yong; Zhuang, Wu; Ma, Zhiyong; Hu, Yanping; Li, Gaofeng; Dong, Xiaorong; Ahn, Myung-JuAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 4
- Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)Liu, S. Y. M.; Zhou, Q.; Lu, C.; Deng, J. Y.; Wang, Z.; Li, Y. S.; Zheng, M. M.; Xu, B. F.; Dong, X. R.; Du, Y. Y.; Cui, J. W.; Chu, Q.; Bai, X. Y.; Sun, Y. L.; Li, A.; Xu, C-R.; Wang, B. C.; Chen, H. J.; Yang, J. J.; Wu, Y. L.
- A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)Zhang, L.; Fang, W.; Yu, Q.; Zhang, H.; Wu, G.; Wu, D.; Lin, Y.; Zhu, J.; Chen, J.; Hu, X.; Lan, B.; Zhou, Z.; Lin, H.; Wang, Z.; Lei, X.; Pan, S.; Chen, L.; Zhang, J.; Kong, T.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFRmutated non-small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.
1被引17阅读
